Description: Albireo Limited is a holding company for Albireo AB, a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008 and is backed by top-tier life science investors such as Phase4 Ventures, TPG Biotech, TVM Capital Life Science and Aberdeen Asset Management, as well as AstraZeneca. Albireo Limited is incorporated and registered in England and Wales, and its wholly owned subsidiaries are located in Gothenburg, Sweden and Boston, Massachusetts. For more information on Albireo, please visit www.albireopharma.com
Home Page: www.albireopharma.com
ALBO Technical Analysis
10 Post Office Square
Boston,
MA
02109
United States
Phone:
857 254 5555
Officers
| Name | Title |
|---|---|
| Mr. Ronald H. W. Cooper | CEO, Pres & Director |
| Mr. Simon Nicolas Reade Harford | CFO & Treasurer |
| Ms. Martha J. Carter | Chief Regulatory Officer |
| Dr. Per-Goran Gillberg Ph.D. | Co-Founder & VP of Devel. |
| Dr. Jan P. Mattsson Ph.D. | Chief Scientific Officer, MD (Sweden) & Co-Founder |
| Ms. Joan Connolly | Chief Technology Officer |
| Mr. Jason G. Duncan | Chief Legal Officer, Gen. Counsel & Sec. |
| Ms. Michelle Graham | Chief HR Officer |
| Dr. Kristina Torfgard | VP & Global Project Head |
| Ms. Pamela Stephenson M.P.H. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3049 |
| Price-to-Sales TTM: | 7.3476 |
| IPO Date: | 2007-05-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 130 |